These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38845840)

  • 1. The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study.
    Wang Y; Xu Y; Liu X; Li C; Wang J; Zhang X; Shao B; Zhang J
    Gland Surg; 2024 May; 13(5):654-662. PubMed ID: 38845840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study.
    Li Q; Wang Y; Zhu M; Gu Y; Tang Y
    Gland Surg; 2021 Dec; 10(12):3389-3402. PubMed ID: 35070899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.
    Ye G; Chen P; Liu X; He T; Pivot X; Pan R; Zhou D; Zhu L; Zhang K; Li W; Yang S; Lin J; Cai G; Huang H
    Gland Surg; 2024 Mar; 13(3):374-382. PubMed ID: 38601287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study.
    Liu L; Zhu M; Wang Y; Li M; Gu Y
    World J Surg Oncol; 2023 Dec; 21(1):389. PubMed ID: 38114991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study.
    Li F; Liang Y; Luo M; Shen J; Zhou T; Liang Y; Tang X; Yuan H; Zeng J
    Front Oncol; 2023; 13():1041111. PubMed ID: 36793595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis.
    Mao X; Lv P; Gong Y; Wu X; Tang P; Wang S; Zhang D; You W; Wang O; Zhou J; Li J; Jin F
    Front Oncol; 2022; 12():855512. PubMed ID: 35463365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant pyrotinib plus nab-paclitaxel, doxorubicin, and cyclophosphamide for HER2-positive locally advanced breast cancer: a retrospective case-series study.
    Yao DS; Wang W; Chang JY; Zhang Y; Zhang HW; Xu JX; Cai HF
    Gland Surg; 2021 Dec; 10(12):3362-3368. PubMed ID: 35070896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.
    Zhong X; He P; Chen J; Yan X; Wei B; Zhang Z; Bu H; Li J; Tian T; Lv Q; Wang X; Li H; Wang J; Huang J; Suo J; Liu X; Zheng H; Luo T
    Gland Surg; 2022 Jan; 11(1):216-225. PubMed ID: 35242683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
    Man X; Huang J; Sun S; Zhou D; Zhang B; Fang S; Zheng F; Li C; Wang X; Huang W; Wang L; He Q; Fu H; Zhang Y; Liu C; Dong L; Zhao X; Xu L; Sun X; Fan B; Song L; Zhou Z; Yu J; Li H
    Clin Transl Med; 2024 May; 14(5):e1687. PubMed ID: 38738791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.
    Xuhong J; Qi X; Tang P; Fan L; Chen L; Zhang F; Tan X; Yan W; Zhong L; He C; Liang Y; Ren L; Wang M; Zhang Y; Jiang J
    Oncologist; 2020 Dec; 25(12):e1909-e1920. PubMed ID: 33000490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
    Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
    Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of pyrotinib-based regimens in HER2 positive metastatic breast cancer: A retrospective real-world data study.
    Dai L; Gao T; Guo R; Chen Y; Wang J; Zhou S; Tang Y; Chen D; Huang S
    Neoplasia; 2024 Oct; 56():101029. PubMed ID: 39024777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ​Efficacy and safety of pyrotinib in combination with albumin‑bound paclitaxel for the treatment of HER2‑positive advanced breast cancer: A real‑world study.
    Yang L; Zheng L; Kong F; Tian X; Zhang S; Pu P
    Oncol Lett; 2023 Jul; 26(1):312. PubMed ID: 37332328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial.
    Wang W; Zhang J; Chang JY; Yao DS; Hu F; Liang YP; Shen Y; Liu YQ; Qi HH; Tong JB; Cai HF
    Gland Surg; 2023 Feb; 12(2):208-214. PubMed ID: 36915823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
    Wang C; Zhou Y; Lin Y; Mao F; Guan J; Zhang X; Shen S; Wang X; Zhang Y; Pan B; Zhong Y; Peng L; Cao X; Yao R; Zhou X; Xu C; Xu Y; Sun Q
    BMC Cancer; 2022 Mar; 22(1):269. PubMed ID: 35287613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
    Wu J; Jiang Z; Liu Z; Yang B; Yang H; Tang J; Wang K; Liu Y; Wang H; Fu P; Zhang S; Liu Q; Wang S; Huang J; Wang C; Wang S; Wang Y; Zhen L; Zhu X; Wu F; Lin X; Zou J
    BMC Med; 2022 Dec; 20(1):498. PubMed ID: 36575513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study.
    Yang Y; Jin L; Li Y; Rao N; Gong C; Li S; Wu J; Zhao J; Ding L; Gan F; Zhang J; Feng R; Liu Z; Liu Q
    Chin J Cancer Res; 2024 Feb; 36(1):55-65. PubMed ID: 38455369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study.
    Wang H; Li Y; Qi Y; Zhao E; Kong X; Yang C; Yang Q; Zhang C; Liu Y; Song Z
    Front Oncol; 2022; 12():909426. PubMed ID: 35875123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience.
    Wu F; Chen M; Wang L; Li N; Wu X; Chen X; Hong Y; Li C; Lin L; Chen K; Huang W; Liu J
    Curr Cancer Drug Targets; 2024; 24(5):490-500. PubMed ID: 37916639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological response and safety of albumin-bound paclitaxel as a neoadjuvant treatment for HER2-positive breast cancer compared to docetaxel combined with anti-HER2 therapy: a real-world study.
    Lyu Z; Gao L
    Front Oncol; 2024; 14():1412051. PubMed ID: 39234401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.